6-Iodoindazole CAS 261953-36-0 Puritas > 98.5% (HPLC) Factory

Description:

Nomen chemicum: 6-Iodoindazole

Synonyma: 6-Iodo(1H)indazole;6-Iodo-1H-Indazole

CAS: 261953-36-0

Puritas: >98.5% (HPLC)

Aspectus: Yellow solidus

Clavis media in Axitinib (CAS: 319460-85-0)

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 6-Iodoindazole (CAS: 261953-36-0) with high quality. We can provide COA, worldwide delivery, small and bulk quantities available. If you are interested in this product, please send detailed information includes CAS number, product name, quantity to us. Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	6-Iodoindazole
Synonyma	6-Iodo(1H)indazole;6-Iodo-1H-Indazole
CAS Number	261953-36-0
CATTUS Number	RF2672
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C7H5IN2
M. Pondus	244.04
Liquescens punctum	207.0 ad 211.0℃
Ferveret	358.2±15.0℃
Density	2.082±0.06 g/cm3
Sensitiva	Lux Sensitiva, Aeris Sensitiva
Solubilitas	DMSO (paulo), Methanol (paulo)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Yellow Firmus
1H NMR Imaginum	Congruunt cum Structure
Mass	Conforms
Puritas / Analysis Methodus	>98.5% (HPLC)
Liquescens punctum	207.0 ad 211.0℃
Damnum in Siccatio	<0.50%
Totalis immunditias	<1.50%
Test Standard	Enterprise Standard
Consuetudinem	Clavis media Synthesis Axitinib (CAS: 319460-85-0)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?Please contact: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.

Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Russiam, Coream, Iaponicam, Australiam etc.

Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.

Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.

Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.

Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.

MOQ?Nec MOQ.Parvus ordo placet.

Tempus adferendi? Si intus prosapia, tres dies partus praestatur.

Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.

Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.

Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.

Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

Applicatio:

6-Iodoindazole (CAS: 261953-36-0) pro mediis pharmaceuticis adhibetur.6-Iodoindazole est clavis media synthesis Axitinib (CAS: 319460-85-0).Ianuarii 27, 2012, axitinib FDA approbata curationem cancer renis (cella carcinoma renum) comprobavit, quae alia medicamenta inenarrabilia sunt.Inlyta a Pfizer confici et venditur, et oralis pilula bis in die sumpta est.Carcinoma renum cellula genus est tumoris ex cellulis endothelialibus tubulares oriundis.Axitinib quidam interdum kinases vocati impedire possunt munus in tumore incrementi et metastasi ludentes.Axitinib inhibitor kinasus tyrosinus parvus est molecula, efficax contra plures scuta, receptores 1 2 et VEGF, inhibitor (IC50s = 1.2, 0.25, et 0.29 nM pro VEGFR1, -2, et -3, respective) .